117 related articles for article (PubMed ID: 38658095)
21. Diacerein-mediated inhibition of IL-6/IL-6R signaling induces apoptotic effects on breast cancer.
Bharti R; Dey G; Ojha PK; Rajput S; Jaganathan SK; Sen R; Mandal M
Oncogene; 2016 Jul; 35(30):3965-75. PubMed ID: 26616855
[TBL] [Abstract][Full Text] [Related]
22. [Doublecortin-like kinase 1 activates Hippo pathway to promote migration, invasion and proliferation of pancreatic cancer cells].
Yan R; Liang ZW; Liu HS; Ge Y; An GY
Zhonghua Zhong Liu Za Zhi; 2023 Jul; 45(7):594-604. PubMed ID: 37462016
[No Abstract] [Full Text] [Related]
23. DCLK1 inhibition attenuates tumorigenesis and improves chemosensitivity in esophageal squamous cell carcinoma by inhibiting β-catenin/c-Myc signaling.
Zhang L; Zhou S; Guo E; Chen X; Yang J; Li X
Pflugers Arch; 2020 Aug; 472(8):1041-1049. PubMed ID: 32533239
[TBL] [Abstract][Full Text] [Related]
24. [The inhibition effects of apatinib on cell proliferation, migration and apoptosis in esophageal carcinoma via Ras/Raf/MEK/ERK and JAK2/STAT3 pathways].
Feng Y; Zhou MY; Sun F; Kong Z; Wang J; Sun ZQ; Hu LJ; Wang JL; Hua Q; Yu JP
Zhonghua Zhong Liu Za Zhi; 2019 Apr; 41(4):263-275. PubMed ID: 31014051
[No Abstract] [Full Text] [Related]
25. DCLK1 plays an important role in colorectal cancer tumorgenesis through the regulation of miR-200c.
Mohammadi Y; Tavangar SM; Saidijam M; Amini R; Etemadi K; Karimi Dermani F; Najafi R
Biomed Pharmacother; 2018 Jul; 103():301-307. PubMed ID: 29656186
[TBL] [Abstract][Full Text] [Related]
26. Application of RNA-sequencing to identify transcriptome modification by DCLK1 in colorectal cancer cells.
Li L; Mei H; Commey ANA
Cancer Gene Ther; 2020 Sep; 27(9):691-701. PubMed ID: 31636360
[TBL] [Abstract][Full Text] [Related]
27. DCLK1 integrates induction of TRIB3, EMT, drug resistance and poor prognosis in colorectal cancer.
Makino S; Takahashi H; Okuzaki D; Miyoshi N; Haraguchi N; Hata T; Matsuda C; Yamamoto H; Mizushima T; Mori M; Doki Y
Carcinogenesis; 2020 May; 41(3):303-312. PubMed ID: 31562741
[TBL] [Abstract][Full Text] [Related]
28. The Histone Demethylase KDM3A, Increased in Human Pancreatic Tumors, Regulates Expression of DCLK1 and Promotes Tumorigenesis in Mice.
Dandawate P; Ghosh C; Palaniyandi K; Paul S; Rawal S; Pradhan R; Sayed AAA; Choudhury S; Standing D; Subramaniam D; Padhye SB; Gunewardena S; Thomas SM; Neil MO; Tawfik O; Welch DR; Jensen RA; Maliski S; Weir S; Iwakuma T; Anant S; Dhar A
Gastroenterology; 2019 Dec; 157(6):1646-1659.e11. PubMed ID: 31442435
[TBL] [Abstract][Full Text] [Related]
29. DCLK1 Expression and its Functional Significance in Intrahepatic Cholangiocarcinoma and Bil-IN Stage.
Fukushima NM; Adachi T; Tanaka T; Matsushima H; Imamura H; Hara T; Soyama A; Hidaka M; Kanetaka K; Eguchi S
Anticancer Res; 2024 Jun; 44(6):2417-2424. PubMed ID: 38821583
[TBL] [Abstract][Full Text] [Related]
30. Enhanced anti-colorectal cancer effects of carfilzomib combined with CPT-11 via downregulation of nuclear factor-κB in vitro and in vivo.
Tang W; Su G; Li J; Liao J; Chen S; Huang C; Liu F; Chen Q; Ye Y
Int J Oncol; 2014 Sep; 45(3):995-1010. PubMed ID: 24968890
[TBL] [Abstract][Full Text] [Related]
31. MicroRNA-424 inhibits cell migration, invasion, and epithelial mesenchymal transition by downregulating doublecortin-like kinase 1 in ovarian clear cell carcinoma.
Wu X; Ruan Y; Jiang H; Xu C
Int J Biochem Cell Biol; 2017 Apr; 85():66-74. PubMed ID: 28161486
[TBL] [Abstract][Full Text] [Related]
32. Alternative splice variants of DCLK1 mark cancer stem cells, promote self-renewal and drug-resistance, and can be targeted to inhibit tumorigenesis in kidney cancer.
Ge Y; Weygant N; Qu D; May R; Berry WL; Yao J; Chandrakesan P; Zheng W; Zhao L; Zhao KL; Drake M; Vega KJ; Bronze MS; Tomasek JJ; An G; Houchen CW
Int J Cancer; 2018 Sep; 143(5):1162-1175. PubMed ID: 29577277
[TBL] [Abstract][Full Text] [Related]
33. DCLK1 might be a therapeutic target of osthole against cervical cancer.
Pan L; Zhang X; Wang D; Huang M; Huang Q; Duan P; Mei J
Pharmazie; 2021 Oct; 76(10):503-506. PubMed ID: 34620279
[TBL] [Abstract][Full Text] [Related]
34. Cytoplasmic expression of DCLK1-S, a novel DCLK1 isoform, is associated with tumor aggressiveness and worse disease-specific survival in colorectal cancer.
Kalantari E; Ghods R; Saeednejad Zanjani L; Rahimi M; Eini L; Razmi M; Asadi-Lari M; Madjd Z
Cancer Biomark; 2022; 33(3):277-289. PubMed ID: 34958000
[TBL] [Abstract][Full Text] [Related]
35. Allicin Inhibits Proliferation and Invasion in Vitro and in Vivo via SHP-1-Mediated STAT3 Signaling in Cholangiocarcinoma.
Chen H; Zhu B; Zhao L; Liu Y; Zhao F; Feng J; Jin Y; Sun J; Geng R; Wei Y
Cell Physiol Biochem; 2018; 47(2):641-653. PubMed ID: 29794468
[TBL] [Abstract][Full Text] [Related]
36. Pien Tze Huang inhibits tumor cell proliferation and promotes apoptosis via suppressing the STAT3 pathway in a colorectal cancer mouse model.
Zhuang Q; Hong F; Shen A; Zheng L; Zeng J; Lin W; Chen Y; Sferra TJ; Hong Z; Peng J
Int J Oncol; 2012 May; 40(5):1569-74. PubMed ID: 22218594
[TBL] [Abstract][Full Text] [Related]
37. Role of doublecortin-like kinase 1 and leucine-rich repeat-containing G-protein-coupled receptor 5 in patients with stage II/III colorectal cancer: Cancer progression and prognosis.
Kang XL; He LR; Chen YL; Wang SB
World J Gastroenterol; 2020 Nov; 26(43):6853-6866. PubMed ID: 33268966
[TBL] [Abstract][Full Text] [Related]
38. Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing.
Liu Y; Ferguson FM; Li L; Kuljanin M; Mills CE; Subramanian K; Harshbarger W; Gondi S; Wang J; Sorger PK; Mancias JD; Gray NS; Westover KD
Cell Chem Biol; 2020 Oct; 27(10):1229-1240.e4. PubMed ID: 32755567
[TBL] [Abstract][Full Text] [Related]
39. The Essential Role of DCLK1 in Pathogenesis, Diagnostic Procedures and Prognostic Stratification of Colorectal Cancer.
Gzil A; Szylberg Ł; Jaworski D; Dominiak J; Zarębska I; Grzanka D
Anticancer Res; 2019 Jun; 39(6):2689-2697. PubMed ID: 31177103
[TBL] [Abstract][Full Text] [Related]
40. Plasma DCLK1 is a marker of hepatocellular carcinoma (HCC): Targeting DCLK1 prevents HCC tumor xenograft growth via a microRNA-dependent mechanism.
Sureban SM; Madhoun MF; May R; Qu D; Ali N; Fazili J; Weygant N; Chandrakesan P; Ding K; Lightfoot SA; Houchen CW
Oncotarget; 2015 Nov; 6(35):37200-15. PubMed ID: 26468984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
